secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2025-06-26T23:59:59+00:00
Accession:  0001140361-25-023732
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Opus Genetics VEGA-3 Phase 3 trial meets primary endpoint for presbyopia treatment
--------------------------------------------------------------------------------

- 27.2% of patients on drug achieved ≥15-letter DCNVA gain vs 11.5% placebo (p<0.0001) at 12h post-dose on Day 8.
- Safety profile consistent with prior trials; no treatment-related serious adverse events reported.
- No evidence of tachyphylaxis over the 6-week study period.
- NDA submission to FDA planned for the second half of 2025.
- Cash on hand expected to fund operations into H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000114036125023732/0001140361-25-023732-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000114036125023732/ef20051231_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-023732

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer